Učitavanje...
Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
BACKGROUND: Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcome...
Spremljeno u:
| Izdano u: | BMC Endocr Disord |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4630836/ https://ncbi.nlm.nih.gov/pubmed/26527413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-015-0064-8 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|